Articles tagged with Hematopoietic Stem Cells
Researchers have demonstrated a new method to obtain donor stem cells for bone marrow transplants using a combination of Viagra and Plerixafor, which can be collected from the blood more quickly and with fewer side effects than traditional methods.
Researchers found that Viagra, combined with Plerixafor, rapidly mobilizes blood stem cells from the bone marrow into the bloodstream in mice. This approach is nearly as effective as the current standard protocol and may be a more attractive option for patients who are very ill or elderly or have undergone chemotherapy.
Researchers at UCLA developed a therapy that permanently boosts the body's ability to produce invariant natural killer T cells (iNKT cells), which attack human tumors. The treatment, engineered from hematopoietic stem cells, effectively suppressed tumor growth in mice with multiple myeloma and melanoma.
Researchers studied nanoparticle uptake in human stem cells and found minor effects on gene expression. The nanoparticles were encapsulated in lysosomes, ensuring their storage and preventing cell damage.
Researchers at Stanford Medicine developed an antibody treatment that enables mice to accept haploidentical hematopoietic stem cell transplants without immunosuppression. This breakthrough could transform the treatment of immune disorders and increase organ availability for transplantation.
Research reveals SIRT1's crucial role in maintaining regenerative potential of CML leukemic stem cells and promoting leukemia development. The study suggests targeting persistent leukemic stem cells with kinase-independent metabolic alterations.
Researchers tracked and quantified blood cell production from hematopoietic stem cells, revealing that red blood cells are the default pathway for all myeloid progenitors. This finding has important implications for understanding disorders such as anemia and blood cancers.
Researchers have developed a more precise gene-editing technique to reduce DNA breaks and prevent cancer in stem cells. This breakthrough could improve the safety of CRISPR treatments for inherited blood disorders.
A team of scientists has found that an analogue of vitamin B3, nicotinamide riboside, can increase the activity of hematopoietic stem cells and boost their ability to produce new blood cells. This breakthrough has significant implications for stem-cell therapy patients, particularly those undergoing chemotherapy or radiotherapy.
Harvard engineers create injectable sponge-like gel to enhance T-cell production and diversity after bone marrow transplantation, improving the immune system's ability to fight infections. The device reduces graft-versus-host disease and increases T-cell recovery rates.
Researchers at Stanford University School of Medicine developed an antibody-based treatment that gently eliminates diseased blood-forming stem cells in the bone marrow. This could circumvent the need for harsh chemotherapy or radiation to prepare people for transplant, expanding the number of patients who can benefit from the procedure.
Researchers at Kobe University found that vitamin D signaling fuels the growth of macrophages in bone marrow, leading to myelofibrosis and bone hardening. A low-vitamin D diet can prevent or treat the condition.
Researchers have identified two functional populations of hematopoietic stem cells: 'primed' and 'reserve', which act under normal conditions and during times of stress, respectively. The reserve cells are protected by N-cadherin+ bone-lining cells, which provide survival factors to support their function.
The Blood editors have selected the top 10 manuscripts of 2018, showcasing notable advances in various hematological disorders. These studies highlight promising treatments for B-cell precursor acute lymphoblastic leukemia and classical Hodgkin lymphoma, as well as novel therapeutic strategies for immune thrombocytopenia.
Researchers at the University of Delaware have developed a novel approach to gene therapy using microparticles that deliver gene-regulating material to hematopoietic stem and progenitor cells. This technology could potentially treat inherited blood disorders such as sickle cell anemia and thalassemia by altering the genetic defect in t...
Researchers at Columbia University Irving Medical Center found that circulating white blood cells from donors contain matured cells that educate recipients' immune system to be tolerant of donated tissues. The study suggests new strategies for managing organ transplantation and reducing immunosuppression.
Healthy blood stem cells exhibit a similar number of DNA mutations as those found in leukemic cells, suggesting that the location of these mutations is more relevant than their quantity. This study's findings have implications for understanding the origins of leukemia and developing targeted treatments.
Researchers studied 3.6 million pregnancies and found beta-blockers not associated with a large increase in cardiac or general birth defects. The risk estimates were generally consistent across Nordic and US data.
Researchers have identified mutations defining two common subtypes of MPAL, B/myeloid and T/myeloid, and shown that some patients may benefit from targeted therapies. The study provides a genetically based framework for designing clinical trials to develop more effective treatments.
A new study identifies HIF1A, a gene that regulates metabolic changes and oxygen levels in cells, as a potential therapeutic target for treating myelodysplastic syndromes (MDS). The researchers found that inhibiting HIF1A reversed a broad spectrum of MDS symptoms in genetic mouse models.
Researchers have identified a way to expand blood-forming adult stem cells from human umbilical cord blood, increasing their availability for transplant patients. This breakthrough could lead to more people being able to receive life-saving treatments without a suitable bone marrow match.
Research at Osaka University reveals SATB1's vital role in maintaining pluripotency of hematopoietic stem cells, influencing self-renewal ability and lymphoid lineage differentiation. High SATB1 expression enhances lymphoid differentiation ability.
Researchers at the University of Vienna discovered a mechanism that regulates HSCs' delicate balance between activation and dormancy, ensuring proper blood cell production. The study found that a feedback loop involving two intracellular signalling pathways maintains this balance, preventing exhaustion and potential death.
Researchers at Stowers Institute for Medical Research discovered a global regulatory element within the Hoxb cluster that controls its expression in blood-forming stem cells. This mechanism helps maintain normal hematopoiesis and prevents acute myeloid leukemia by regulating Hoxb cluster genes in a methylation-dependent manner.
Researchers at Kanazawa University identified a molecule called Spred1 that supports blood-cell production during dietary stress. In contrast, Spred1 deficiency promotes HSC self-renewal and resistance to physiological stress, but also increases the risk of certain cancers.
Japanese researchers at Osaka University have identified a key cellular protein, Ebf3, involved in maintaining the bone marrow niche. The study found that Ebf3-deficient CAR cells take on bone-synthesizing properties, which has significant clinical implications for regenerative therapies.
A new imaging test can detect bone marrow engraftment as early as days after a transplant, giving patients and doctors a more accurate assessment of the treatment's success. This breakthrough could help patients avoid painful biopsies and rapidly respond to potential complications, potentially saving lives.
Researchers discover that training the innate immune system through β-glucan can prime it to respond more robustly to threats, including infections and chemotherapy. This approach could lead to new strategies for preventing neutropenia and improving treatment outcomes.
Researchers developed a gene therapy approach using CAR T-cells to target and destroy HIV-infected cells, achieving sustained immunity of over two years in test animals. The engineered cells effectively attacked and killed HIV-infected cells without adverse effects.
New research reveals obesity causes durable and harmful changes to hematopoietic stem cell compartment, potentially impacting blood cancer development. The study also suggests lifestyle choices like diet may durably impact blood formation.
A new harvesting method has been developed by the Massachusetts General Hospital team, which rapidly produces superior stem cells for bone marrow transplantation. The procedure, which combines GRO-beta and AMD3100 injections, mobilizes stem cells in just 15 minutes, making it less painful and disruptive for donors.
Scientists have made a breakthrough in treating neurodegenerative disorders and lysosomal storage diseases by transplanting hematopoietic stem cells directly into the brain, achieving therapeutic benefits faster than traditional methods. This innovative technique could pave the way for new treatments for Parkinson's, Alzheimer's, and o...
Researchers have identified a distinct subset of hematopoietic stem cells capable of fully repopulating the bone marrow after transplantation. These cells, marked by specific surface markers, were found to be essential for successful bone marrow transplantation in nonhuman primates and show promise for human applications.
Researchers found that antimicrobial peptide R-Spondin1 stimulates intestinal stem cells to differentiate into Paneth cells, which secrete alpha-defensins with strong antimicrobial activity. Administration of R-Spondin1 restored gut microbiota in mice with graft-versus-host disease, preventing depletion of Paneth cells and dysbiosis.
German researchers have made significant advancements in human gene therapy, including virotherapy capable of destroying tumor cells and engineered hematopoietic stem cell delivery systems. These innovations hold promise for treating immunodeficiencies and genetic diseases.
Researchers in Germany have demonstrated that temporarily preventing hematopoietic stem cells from dying can improve HSC transplantation outcomes. By inhibiting apoptosis, HSCs can establish themselves in the bone marrow and produce healthy blood cells more effectively.
Recent research reveals that bacterial infections activate hematopoietic stem cells in the bone marrow, inducing proliferation but also causing stress and reduced ability to produce blood. This finding suggests a link between bacterial infections and dysregulated hematopoiesis, highlighting potential prevention methods for blood diseases.
Researchers at the German Cancer Research Center create a new barcode system to study blood cell development, revealing two major branches that give rise to different cell types. The technology allows for precise tracking of individual cells and has implications for cancer research and other tissue studies.
A clinical trial has demonstrated the safety and effectiveness of a new treatment using virus-specific cells to treat viral infections in patients who have received a hematopoietic stem cell transplant. The treatment resulted in an overall complete or partial response rate of 92% in patients with severe, drug-resistant viral infections.
Researchers found that cell fate decision is not a unique programmed event, but rather the outcome of a dynamic process where cells explore different molecular possibilities before reaching a stable state. This process is reminiscent of trial-and-error learning and highlights the complexity of human hematopoietic cell fate commitment.
Researchers found that hematopoietic stem cells can directly detect bacterial infections and begin dividing without signals from growth factors. This reaction damages the cells' regenerative ability, potentially leading to malignant diseases at advanced age.
Researchers at Weill Cornell Medicine have developed a method to generate healthy blood-forming stem cells from readily available cells lining blood vessels. This breakthrough enables the creation of an unlimited supply of new, healthy blood cells for transplantation, which may help cure patients with genetic and acquired blood diseases.
Researchers have identified a way to prevent graft-versus-host disease after stem cell transplants while preserving anti-cancer effects on fighting leukemia and lymphoma. By depleting specific donor T cells, the regimen may stop GVHD without subduing cancer-killing immune cells.
A study using human stem cells found that deep space radiation may increase the risk of leukemia in humans. The research team identified a dietary supplement as a potential protector against these effects.
Scientists have developed biomaterials that can mimic the characteristics of bone marrow, allowing them to alter blood cell development. The study's findings hold promise for treating hematopoietic cancers such as leukemia and improving our understanding of bone marrow failure.
Researchers developed an algorithm that uses Deep Learning to predict the decision of hematopoietic stem cells to become a certain cell type. This enables earlier detection and analysis of blood cell development, paving the way for new treatments and insights into developmental traits.
A study of 281 patients with aggressive MS who underwent autologous hematopoietic stem cell transplantation found a 46% five-year progression-free survival rate. Younger age, relapsing form of MS, and fewer prior immunotherapies were associated with better outcomes.
Researchers at Rockefeller University Press discovered that tumor suppressor protein RUNX1 can promote AML in some cases, particularly when combined with mutant FLT3. Targeting RUNX1 may be an effective treatment for certain AML patients, potentially offering a promising therapeutic strategy.
Researchers define how genetic factors affect blood-forming stem cells' regenerative properties, accelerating or hindering their ability to restore the immune system. The findings highlight two molecular mechanisms that could be manipulated to increase hematopoietic stem cell regeneration.
A team of Japanese researchers revealed the mechanism for fever and bone pain caused by G-CSF, which is essential for treating hematological malignancies. The study found that PGE2 produced by neutrophils governed by sympathetic nervous system is behind the unpleasant symptoms caused by G-CSF.
Researchers found that palliative care intervention reduced decline in quality of life and depression among patients with hematologic malignancies undergoing stem cell transplantation. Caregivers also reported a smaller increase in depression.
Magenta Therapeutics secures license to transform blood stem cell transplants with new technologies. The suite of technologies could improve the lives of patients with blood diseases and immune disorders.
A new study reveals that non-blood cell forming stem cells in human bone marrow play a crucial role in maintaining the hematopoietic microenvironment and retain self-renewal potential after primary and secondary transplantations. The findings suggest an alternative to traditional hematopoietic stem cell transplantation.
Researchers identified amino acid valine as crucial for hematopoietic stem cell maintenance. A valine-free diet with gradual reintroduction led to successful long-term engraftment of healthy donor cells in mice.
Researchers have identified HDAC7 as a transcriptional repressor involved in B lymphocyte generation and identity. The study reveals that HDAC7 is essential for B cell development, maintaining its lymphoid identity by silencing lineage-inappropriate genes.
Researchers developed a lentiviral vector-based gene therapy approach to deliver normal copies of the alpha-iduronidase gene to HSCs, indicating safety and efficacy in mice. The study sets the stage for a clinical trial to determine if MPS I patients can be successfully treated with this approach.
Researchers discover that inflammatory signaling in bone marrow tumor environment drives malignancy and predicts leukemia development. The study reveals that mesenchymal stem cells under stress release inflammatory molecules causing DNA damage in hematopoietic stem cells, increasing leukemia risk.
Researchers have identified RNA-based biomarkers that distinguish between normal, aging hematopoietic stem cells and leukemia stem cells associated with secondary acute myeloid leukemia. The findings suggest a new way to predict leukemic relapse early and identify potential targets for new drug development.
Researchers have identified a crucial protein complex in hematopoiesis, the process of creating healthy blood cells. MED12 mutations are linked to several cancers, including leukemia and prostate cancer. Deleting this protein complex disrupts blood cell growth and leads to cancer.
JAX researchers found a precise way to identify the kind of cell that leads to a given case of leukemia through whole-genome profiling of open chromatin. This approach may provide insight into tumor subtypes and possibly diagnostic and therapeutic benefits.